Hemorrhagic transformation in patients with acute ischaemic stroke and an indication for anticoagulation

European Journal of Neurology

Volumn 20, Issue 6, 2013, Pages 962-967

  Marsh, E B ^a   Llinas, R H ^a   Hillis, A E ^a   Gottesman, R F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Cerebral hemorrhage; Cerebral infarction; Cerebrovascular diseases and cerebral circulation; Renal failure; Stroke

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; DEEP VEIN THROMBOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMORRHAGIC TRANSFORMATION; HUMAN; HYPERCOAGULABILITY; KIDNEY FUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE PATIENT; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE;

EID: 84877667507     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12126     Document Type: Article

References (23)

1. Coull BM, Williams LS, Goldstein LB, et al. Joint Stroke Guideline Development Committee of the American Academy of Neurology, American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002; 33: 1934-1942.
2. Khatri P, Wechsler LR, Broderick JP. Intracranial hemorrhage associated with revascularization therapies. Stroke 2007; 38: 431-440.
3. Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996; 46: 341-345.
4. Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction - a prospective study. Stroke 1986; 17: 179-185.
5. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-1272.
6. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
7. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in acute embolic stroke trial. Lancet 2000; 355: 1205-1210.
8. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316.
9. Mohr JP, Thompson JL, Lazar LM, et al. Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451.
10. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649.
11. Duke RJ, Bloch RF, Turpie AG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986; 105: 825-828.
12. Kleinman JT, Hillis AE, Jordan LC. ABC/2: estimating intracerebral haemorrhage volume and total brain volume, and predicting outcome in children. Dev Med Child Neurol 2011; 53: 281-284.
13. Bradley WG. MR appearance of hemorrhage in the brain. Radiology 1993; 189: 15-26.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
15. Longstreth WT Jr, Katz R, Tirschwell DL, Cushman M, Psaty BM. Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med 2010; 28: 359-363.
16. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
17. Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. New Engl J Med 2012; 367: 625-635.
18. Laino C. News from the international stroke conference: new analysis shows diastolic blood pressure, renal impairment risk factors for intracranial hemorrhage. Neurol Today 2012; 12: 12.
19. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589.
20. Park JH, Ko Y, Kim WJ, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology 2012; 78: 421-426.
21. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
22. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-2118.
23. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.